All questionsSpecific populations: Otezla (apremilast), all indications5 questions · 1 sourceSpecific populationsDoes Otezla need a dose adjustment for kidney impairment?“OTEZLA pharmacokinetics were characterized in adult subjects with mild, moderate, and severe renal impairment as defined by a creatinine clearance of 60-89, 30-59, and less than 30 mL per minute,” (opens the source at this quote in a new tab)CopyFlag“respectively, by the Cockcroft–Gault equation. No dosage adjustment is needed in patients with mild or moderate renal impairment. In adult patients with severe renal impairment, reduce the maintenance dosage to OTEZLA 30 mg once daily. In pediatric patients 6 years of age and older and weighing at least 20 kg with psoriatic arthritis or moderate to severe plaque psoriasis and severe renal impairment, reduce the maintenance dosage to OTEZLA 30 mg once daily for pediatric patients weighing at least 50 kg and to OTEZLA 20 mg once daily for pediatric patients weighing 20 kg to less than 50 kg [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlag“For initial dosage titration in adult patients with severe renal impairment (creatinine clearance [CLcr] of less than 30 mL per minute estimated by the Cockcroft–Gault equation), titrate OTEZLA using only the AM schedule listed in Table 1 and skip the PM doses. The recommended maintenance dosage in this group is OTEZLA 30 mg once daily [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlagNote: The 8.6 Renal Impairment passage continues from page 15 to page 16 of the Prescribing Information.Can Otezla XR be used in severe kidney impairment?“OTEZLA XR is not recommended for adult patients with severe renal impairment; the appropriate dosage for these patients has not been determined [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlag“OTEZLA XR is not recommended for pediatric patients with severe renal impairment; the appropriate dosage for these patients has not been determined [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlag“The pharmacokinetics of OTEZLA XR has not been evaluated in patients with renal impairment. In patients with severe renal impairment, it is recommended that OTEZLA be used instead of OTEZLA XR [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].” (opens the source at this quote in a new tab)CopyFlagDoes Otezla need a dose adjustment for liver impairment?“Apremilast pharmacokinetics were characterized in subjects with moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment. No dosage adjustment is necessary in these patients.” (opens the source at this quote in a new tab)CopyFlag“Patients with Hepatic Impairment: The pharmacokinetics of apremilast is not affected by moderate or severe hepatic impairment.” (opens the source at this quote in a new tab)CopyFlagPregnancy and breastfeedingCan Otezla be used during pregnancy?“Available data with OTEZLA use in pregnant women have not identified a drug-associated risk of major birth defects or adverse maternal or fetal outcomes (see Data).” (opens the source at this quote in a new tab)CopyFlag“Based on findings from animal reproduction studies, OTEZLA/OTEZLA XR may increase the risk for fetal loss (see Data). Advise pregnant women of the potential risk of fetal loss.” (opens the source at this quote in a new tab)CopyFlag“A pregnancy registry conducted by the Organization of Teratology Information Specialists (OTIS) in the United States and Canada assessed the risk of major birth defects in liveborn infants of women with psoriatic arthritis, psoriasis, or Behçet’s Disease exposed to apremilast in the first trimester. The study compared pregnant women treated with apremilast (n = 15) with disease matched pregnant women who were not exposed to apremilast (n = 106). In the apremilast-exposed cohort, there were no reports of liveborn infants with major birth defects nor miscarriages. One stillbirth was reported in the apremilast exposed cohort. These data are limited by the small sample size of apremilast-exposed pregnancies.” (opens the source at this quote in a new tab)CopyFlagCan Otezla be used while breastfeeding?“There are no data on the presence of apremilast in human milk, its effects on the breastfed infant, or its effects on milk production. However, apremilast was detected in the milk of lactating mice (see Data). When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for OTEZLA/OTEZLA XR and any potential adverse effects on the breastfed infant from OTEZLA/OTEZLA XR or from the underlying maternal condition.” (opens the source at this quote in a new tab)CopyFlag